{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:43:36Z","timestamp":1787510616260,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.clon.2023.11.040","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T03:01:30Z","timestamp":1701140490000},"page":"98-106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Experience of Axillary Radiotherapy for Node-positive Breast Cancer"],"prefix":"10.1016","volume":"36","author":[{"given":"S.","family":"Anderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.L.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Lumsden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Alhasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Cartwright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Marashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2023.11.040_bib1","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2023.11.040_bib2","series-title":"Early and locally advanced breast cancer: diagnosis and management, NICE guideline [NG101]","year":"2018"},{"issue":"2","key":"10.1016\/j.clon.2023.11.040_bib3","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s13193-011-0078-2","article-title":"Complications of axillary lymph node dissection in treatment of early breast cancer: a comparison of MRM and BCS","volume":"2","author":"Brar","year":"2011","journal-title":"Indian J Surg Oncol"},{"key":"10.1016\/j.clon.2023.11.040_bib4","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial","volume":"15","author":"Donker","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2023.11.040_bib5","article-title":"Axillary radiotherapy: an alternative treatment option for adjuvant axillary management of breast cancer","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.clon.2023.11.040_bib7","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/jama.2011.90","article-title":"Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial","volume":"305","author":"Giuliano","year":"2011","journal-title":"JAMA"},{"issue":"24","key":"10.1016\/j.clon.2023.11.040_bib8","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1200\/JCO.2006.07.4062","article-title":"Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011","volume":"25","author":"Lucci","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2023.11.040_bib9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.breast.2022.02.013","article-title":"Patient-reported outcomes one year after positive sentinel lymph node biopsy with or without axillary lymph node dissection in the randomized SENOMAC trial","volume":"63","author":"Appelgren","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.clon.2023.11.040_bib11","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa020128","article-title":"Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation","volume":"347","author":"Fisher","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.clon.2023.11.040_bib12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1200\/JCO.2004.12.108","article-title":"Axillary treatment in conservative management of operable breast cancer: dissection or radiotherapy? Results of a randomized study with 15 years of follow-up","volume":"22","author":"Louis-Sylvestre","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.clon.2023.11.040_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-054365","volume":"11","author":"Goyal","year":"2021","journal-title":"BMJ Open"},{"issue":"16_suppl","key":"10.1016\/j.clon.2023.11.040_bib14","doi-asserted-by":"crossref","first-page":"TPS615","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS615","article-title":"ATNEC: a multicenter, randomized trial investigating whether axillary treatment can be avoided in patients with T1-3N1M0 breast cancer with no residual cancer in the lymph glands after neoadjuvant chemotherapy","volume":"40","author":"Goyal","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2023.11.040_bib15","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"on behalf of the monarchE Committee Members and Investigators. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2\u2212, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.clon.2023.11.040_bib16","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1200\/JCO.20.03639","article-title":"Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer \u2013 the Penelope-B Trial","volume":"39","author":"Loibl","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.clon.2023.11.040_bib17","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.21.02554","article-title":"PALLAS Groups and Investigators. Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42\/AFT-05\/BIG-14-03)","volume":"40","author":"Gnant","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.clon.2023.11.040_bib18","first-page":"289","volume":"3","author":"Iwata","year":"2017","journal-title":"J\u00a0Glob Oncol"},{"issue":"6","key":"10.1016\/j.clon.2023.11.040_bib19","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s12282-021-01263-8","article-title":"Loco-regional therapy and the risk of breast cancer-related lymphedema: a systematic review and meta-analysis","volume":"28","author":"Lin","year":"2021","journal-title":"Breast Cancer"},{"issue":"2","key":"10.1016\/j.clon.2023.11.040_bib20","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10549-016-4089-0","article-title":"Radiation therapy targets and the risk of breast cancer-related lymphedema: a systematic review and network meta-analysis","volume":"162","author":"Shaitelman","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clon.2023.11.040_bib21","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.breast.2023.02.001","article-title":"The influence of axillary surgery and radiotherapeutic strategy on the risk of lymphedema and upper extremity dysfunction in early breast cancer patients","volume":"68","author":"Zheng","year":"2023","journal-title":"Breast"},{"issue":"5","key":"10.1016\/j.clon.2023.11.040_bib22","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0360-3016(02)04273-6","article-title":"Risk of lymphedema after regional nodal irradiation with breast conservation therapy","volume":"55","author":"Coen","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.clon.2023.11.040_bib23","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.ijrobp.2020.10.024","article-title":"The risk of subclinical breast cancer-related lymphedema by the extent of axillary surgery and regional node irradiation: a randomized controlled trial","volume":"109","author":"Boyages","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"25","key":"10.1016\/j.clon.2023.11.040_bib24","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2023.11.040_bib25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2023.11.040_bib26","series-title":"Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer. Diagnostics guidance [DG34]","year":"2018"},{"issue":"13","key":"10.1016\/j.clon.2023.11.040_bib27","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.20.01204","article-title":"APHINITY Steering Committee and Investigators. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years' follow-up","volume":"39","author":"Piccart","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"10.1016\/j.clon.2023.11.040_bib28","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1200\/JCO.21.01532","article-title":"Adjuvant PARP inhibitors in patients with high-risk early-stage HER2-negative breast cancer and germline BRCA mutations: ASCO hereditary breast cancer guideline rapid recommendation update","volume":"39","author":"Tung","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.clon.2023.11.040_bib29","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamaoncol.2020.2965","article-title":"Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a phase 3 randomized clinical trial","volume":"6","author":"Yu","year":"2020","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.clon.2023.11.040_bib30","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/annonc\/mdz158","article-title":"A\u00a0randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study","volume":"30","author":"Loibl","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2023.11.040_bib31","author":"Yuan"},{"issue":"7","key":"10.1016\/j.clon.2023.11.040_bib32","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"KATHERINE Investigators. Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.clon.2023.11.040_bib33","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1200\/jco.2015.33.15_suppl.505","article-title":"Five-year analysis of the phase II NeoSphere trial evaluating four cycles of neoadjuvant docetaxel (D) and\/or trastuzumab (T) and\/or pertuzumab (P)","volume":"33","author":"Gianni","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"10237","key":"10.1016\/j.clon.2023.11.040_bib34","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/S0140-6736(20)30932-6","article-title":"on behalf of the FAST-Forward Trial Management Group. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial","volume":"395","author":"Brunt","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.clon.2023.11.040_bib35","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","article-title":"The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials","volume":"14","author":"Haviland","year":"2013","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clon.2023.11.040_bib36","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1186\/s13063-020-04751-y","volume":"21","author":"Chatterjee","year":"2020","journal-title":"Trials"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655523004557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655523004557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:53:35Z","timestamp":1760543615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655523004557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0936655523004557"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2023.11.040","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Experience of Axillary Radiotherapy for Node-positive Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2023.11.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}]}}